Pravastatin Sodium 20mg Tablets Recalled for CGMP Deviations
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Pravastatin Sodium Tablets, USP, 20mg, 90-count bottles (Lot # 17230810, expiration Mar-26) nationwide due to manufacturing process deviations.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class II classification applies. The source describes CGMP deviations but reports no illnesses or injuries, making this a precautionary manufacturing-compliance recall rather than a safety incident.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is voluntarily recalling Pravastatin Sodium Tablets, USP, 20mg, in 90-count bottles distributed nationwide. The recall affects product manufactured for Northstar Rx LLC, Memphis, TN, with NDC# 16714-559-01. The affected lot is Lot # 17230810 with an expiration date of March 2026.
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified in the manufacturing process. This is a Class II recall, meaning the product is unlikely to cause adverse health consequences but warrants action to prevent potential harm.
Patients taking this medication should contact their pharmacy or healthcare provider. The recall was initiated on March 13, 2025, and classified by the FDA on April 8, 2025. For more information, consult the FDA's drug recall database or contact Glenmark Pharmaceuticals Inc., USA.
The recalled product
- Product
- PRAVASTATIN SODIUM (PRAVASTATIN SODIUM)
- Brand
- PRAVASTATIN SODIUM
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug — Prescription
- Hazard
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot # 17230810
- exp. date Mar-26
UPCs (3)
- 0316714570013
- 0316714559018
- 0316714560014
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 39 recalled by Glenmark Pharmaceuticals Inc., USA under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 39 products in this recall →Related recalls
Same brand · PRAVASTATIN SODIUM
- ModeratePravastatin Sodium Tablets Recalled Due to Manufacturing Practice Deviations
FDA (Drugs) · 2025-04-16
- ModerateGlenmark Pharmaceuticals Recalls Pravastatin Sodium Tablets 80mg
FDA (Drugs) · 2025-04-16
- ModeratePravastatin Sodium Tablets Recalled Due to Manufacturing Deviations
FDA (Drugs) · 2025-04-16
- HighPravastatin Sodium Tablets Recalled for Failed Dissolution Specifications
FDA (Drugs) · 2024-07-24
- HighPravastatin Sodium tablets recalled for manufacturing practice violations
FDA (Drugs) · 2023-03-08
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · cgmp deviation
See all →- SevereZicam Cold Remedy Nasal Swabs Recalled for Microbiological Testing Failures
FDA (Drugs) · 2026-09-02
- ModerateGolden State Medical Supply Recalls Carbamazepine Tablets Due to CGMP Deviations
FDA (Drugs) · 2026-08-26
- HighShoolin Pharma Recalls Tadalafil USP Due to CGMP Deviations
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate USP Recalled for CGMP Deviations Noted During FDA Inspection
FDA (Drugs) · 2026-08-19
- ModerateSildenafil Citrate Recall Due to CGMP Deviations
FDA (Drugs) · 2026-08-19